10-Q: Intelligent Bio Solutions Inc. Reports Increased Revenue but Widening Losses in Q2 2024

Intelligent Bio Solutions Inc. saw a significant increase in revenue but also experienced a larger net loss in the second quarter of fiscal year 2024 compared to the same period last year.

Summary

• Intelligent Bio Solutions Inc. reported a revenue of $764,063 for the three months ended December 31, 2023, a significant increase from $356,679 in the same period of 2022.
• The company's cost of revenue also increased to $564,815 from $112,635 year-over-year, impacting gross profit.
• Government support income decreased to $153,204 from $269,625 in the same quarter of the previous year.
• Operating expenses totaled $2,343,809, which included selling, general, and administrative expenses of $1,705,044 and development and regulatory approval expenses of $348,452.
• The company's net loss for the quarter was $1,976,383, compared to a net loss of $427,071 in the same period of 2022.
• For the six months ended December 31, 2023, revenue was $1,560,157, up from $356,679 in the prior year, while the net loss was $4,408,807 compared to $1,641,149 in 2022.
• The company's cash and cash equivalents stood at $1,119,004 as of December 31, 2023, and they have a working capital deficit of $2,238,430.
• The company has an accumulated deficit of $46,202,418 as of December 31, 2023.
• The company completed a 1-for-12 reverse stock split on January 26, 2024, to regain compliance with Nasdaq listing requirements.

Sentiment

Score: 3

Explanation: The document presents a mixed picture with strong revenue growth offset by significant losses, a going concern warning, and internal control issues. The need for additional capital and the potential for delisting from Nasdaq contribute to a negative sentiment.

Positives

• The company experienced substantial revenue growth, more than doubling year-over-year for both the quarter and six-month periods.
• The company successfully raised $3.79 million in net proceeds through a public offering, providing additional capital.
• The company expanded its market reach into New Zealand and secured new partnerships, indicating growing demand for its drug screening product.
• The company's laboratory partner received accreditation, demonstrating a commitment to product quality and reliability.

Negatives

• The company's net loss significantly increased year-over-year for both the quarter and six-month periods.
• The company has a substantial working capital deficit of $2,238,430.
• The company's cash and cash equivalents of $1,119,004 are insufficient to fund operations for the next twelve months.
• The company has identified material weaknesses in its internal control over financial reporting.
• Government support income decreased significantly compared to the previous year.

Risks

• The company's ability to continue as a going concern is in doubt due to insufficient cash reserves and operating losses.
• The company may not be able to raise additional capital on favorable terms, or at all.
• The company's failure to remediate material weaknesses in internal control over financial reporting could lead to inaccurate financial reporting.
• The company's stock price may be negatively impacted by the sale of a substantial number of shares.
• The company may be delisted from the Nasdaq Capital Market if it fails to maintain the minimum bid price.
• The company may be liable to refund a government grant if it fails to achieve certain milestones.
• The company's licensing agreement for its SGT product may be at risk due to the liquidation of the licensor.

Future Outlook

The company anticipates operating losses for the foreseeable future and expects that its current cash and cash equivalents will be insufficient to fund its operating plan for the next twelve months. The company will need to raise additional funds to continue operations.

Management Comments

• Management is committed to continuing the steps necessary to remediate the control deficiencies that constituted the material weaknesses.
• Management believes that the company's consolidated financial statements and other information contained in the report present fairly, in all material respects, the company's business, financial condition and results of operations for the periods presented.

Industry Context

The company operates in the medical technology sector, focusing on non-invasive testing and screening solutions. The increased revenue suggests a growing market for its drug screening products, while the widening losses highlight the challenges of scaling a business in this sector. The company's focus on innovative and accessible solutions aligns with broader trends in healthcare towards more convenient and patient-friendly diagnostics.

Comparison to Industry Standards

• The company's revenue growth is notable compared to some early-stage medical technology companies, but the significant net losses are a concern.
• The company's reliance on government grants and equity financing is typical for companies in this stage of development, but the need for additional capital raises questions about its long-term financial sustainability.
• The company's working capital deficit is a significant concern, as many companies in the medical technology sector maintain a positive working capital position.
• The company's internal control weaknesses are a serious issue, as most public companies are expected to have robust internal controls.
• Compared to companies like Abbott or Roche, which are established players in the diagnostics market, Intelligent Bio Solutions is still in a very early stage of development and faces significant challenges in scaling its operations and achieving profitability.

Related Party Transactions

• Spiro Sakiris, the company's Chief Financial Officer, purchased 112,727 units in the October 2023 Offering.
• Christopher Towers, a member of the company's Board of Directors, purchased 9,090 units in the October 2023 Offering.

Stakeholder Impact

• Shareholders face the risk of further dilution and potential loss of investment due to the company's need for additional capital and the risk of delisting.
• Employees may be impacted by potential cost-cutting measures or restructuring if the company fails to secure additional funding.
• Customers may be affected by potential delays in product development or delivery if the company's financial situation worsens.
• Suppliers and creditors face increased risk of non-payment if the company's financial situation does not improve.

Next Steps

• The company will need to raise additional capital to fund its operations.
• The company will need to remediate the material weaknesses in its internal control over financial reporting.
• The company plans to discuss the future licensing of SGT products with the University of Newcastle.
• The company will continue to expand its market reach and customer base.

Key Dates

Keywords

Intelligent Bio Solutions, drug screening, biosensor, revenue, net loss, reverse stock split, financial results, going concern, internal control, Nasdaq